Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Kazia Therapeutics will raise $4 million through an institutional placement to improve two drug candidates for treating various cancers
  • 10 million fully paid ordinary shares have been allocated to institutional, professional and sophisticated investors at $0.40 cents per new share
  • Settlement of the placement is expected to occur by the end of the month
  • Kazia’s shares are down 3.23 per cent, with shares trading at 45 cents each

Kazia Therapeutics will raise $4 million to improve its GDC-0084 and Cantrixil cancer programs.

Under the placement, 10 million fully paid ordinary shares have been allocated to institutional, professional and sophisticated investors at $0.40 cents per new share.

Kazia is an innovative oncology-focused biotech company that is currently developing GDC-0084 and TRX-E-002-1 (Cantrixil).

Kazia Chairman Iain Ross is pleased by the strong interest received regarding the placement.

“It is testament to the Company’s growing credibility and prospects that this round has been performed at a premium to our last round, and without the need for warrants, convertible notes, or similar arrangements, and was oversubscribed,” Iain said.

The GDC-0084 novel target therapy is being developed to treat glioblastoma multiforme which is the most common and most aggressive form of primary brain cancer in adults.

The drug candidate entered a phase II clinical trial in 2018 and initial safety data was released in May 2019.

Kazia plans to present further interim clinical data from its ongoing trial at the Society for Neuro-Oncology (SNO) annual meeting in Phoenix, Arizona on November 20-24 2019.

Cantrixil is a third-generation benzopyran molecule that is being developed to treat ovarian cancer. It is currently undergoing a phase I clinical trial in Australia and the United States.

Interim data was presented last month at the ESMO Congress, a global stage for excellence in cancer research, practice-changing data and multidisciplinary discussions.

Cantrixil was granted orphan designation by the U.S. FDA in April 2015, while GDC-0084 was granted orphan designation in February last year.

Settlement of the placement is expected to occur on or around October 31 2019.

Kazia’s shares are down 3.23 per cent, with shares trading at 45 cents each at 3:11 pm AEDT.

KZA by the numbers
More From The Market Herald
The Market Herald Video

" Next Science’s (ASX:NXS) CEO submits resignation

Next Science’s (ASX:NXS) CEO has announced her intention to retire before June 30, 2023.
The Market Herald Video

" Race Oncology (ASX:RAC) completes first-phase Zantrene leukaemia trial

Cancer treatment company Race Oncology (ASX:RAC) has completed the latest stage of its first-phase trial for…
The Market Herald Video

" Immutep (ASX:IMM) publishes “favourable” interim data from second-phase efti trial

Immutep (ASX:IMM) has published new interim data from Part A of its second-phase TACTI-002 trial showing…

" Microba Life Sciences (ASX:MAP) partners with Midnight Health

Microba Life Sciences (ASX:MAP) has signed a strategic partnership agreement with healthcare company, Midnight Health, to…